Rebastinib
- Catalog NO.:A896965
- CAS No. : 1020172-07-9
- Molecular Formula:C30H28FN7O3
- Molecular Weight: 553.59
1. Please click the
![](/usr/uploads/3/201903/xunpan.png.png)
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
CAS Number | 1020172-07-9 | Appearance | |
Catalog Number | A896965 | MDL Number | MFCD19443646 |
Molecular Formula | C30H28FN7O3 | Molecular Weight | 553.59 |
Boiling Point | Melting Point | ||
Flash Point | Density | ||
Synonyms | DCC-2036;N-[3-tert-Butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl]-N'-[2-fluoro-4-[(2-(methylcarbamoyl)pyridin-4-yl)oxy]phenyl]urea;DCC-2036 | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram |
![]() |
||
Signal Word | Warning | UN Number | |
Hazard Statements | H302-H315-H319-H335 | Class | |
Precautionary Statements | P261-P305+P351+P338 | Packing Group |
Description
Rebastinib, also known as DCC-2036, is an orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor DCC-2036 binds to and inhibits the Bcr-Abl fusion oncoprotein by changing the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation; in addition, this agent binds to and inhibits Src family kinases LYN, HCK and FGR and the receptor tyrosine kinases TIE-2 and VEGFR-2. Multitargeted tyrosine kinase inhibitor DCC-2036 may exhibit more potent activity against T315I Bcr-Abl gatekeeper mutant kinases than other Bcr-Abl kinase inhibitors |